Researchers have begun a long-term trial called SOL-X to evaluate a new treatment for wet age-related macular degeneration (wet AMD), a leading cause of vision loss. This trial follows the promising results of the earlier SOL-1 trial, where the treatment, known as AXPAXLI, showed strong potential in maintaining vision and controlling the disease. The first participant was enrolled in April 2026, and the trial aims to assess how well AXPAXLI can improve visual outcomes over an extended period while reducing the frequency of treatments.

For those concerned about aging and eye health, this trial could offer hope. Wet AMD affects millions of people, leading to irreversible vision loss if not treated promptly. AXPAXLI may help maintain vision and potentially prevent further deterioration by providing continuous treatment, which is crucial since current therapies often require frequent injections that can lead to patient dropout. If successful, this treatment could significantly enhance long-term visual health for many individuals.

The SOL-X trial is still in its early stages, with initial results from the previous SOL-1 trial showing encouraging durability and control of the disease. However, it is important to note that while the findings so far are positive, they are not yet conclusive. The SOL-X trial will provide more data on the long-term safety and effectiveness of AXPAXLI over three years, which is essential for determining its real-world benefits.

If you or someone you know is affected by wet AMD, staying informed about new treatments like AXPAXLI could be beneficial. Discussing participation in clinical trials with healthcare providers might also be a way to access cutting-edge therapies while contributing to important research.

Source: globenewswire.com